Swaminathan, B. Et Al. 2018. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.. The Lancet. Neurology , vol.17, no.12 , 1053-1060.

Swaminathan, B., Lavados, P., Sharma, M., Muir, K., Endres, M., Lutsep, H., ... Messé, S. R.(2018). Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.. The Lancet. Neurology , vol.17, no.12, 1053-1060.

Swaminathan, Balakumar Et Al. "Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.," The Lancet. Neurology , vol.17, no.12, 1053-1060, 2018

Swaminathan, Balakumar Et Al. "Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.." The Lancet. Neurology , vol.17, no.12, pp.1053-1060, 2018

Swaminathan, B. Et Al. (2018) . "Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.." The Lancet. Neurology , vol.17, no.12, pp.1053-1060.

@article{article, author={Balakumar Swaminathan Et Al. }, title={Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.}, journal={The Lancet. Neurology}, year=2018, pages={1053-1060} }